Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–9 of 9 results
Advanced filters: Author: Jordi Bruix Clear advanced filters

  • The treatment options available for hepatocellular carcinoma (HCC) vary depending on prognostic factors that include tumour characteristics and clinical status, particularly with regard to liver function. This Review discusses the links between disease phenotype, prognosis and therapy, focusing on the subclassification of patients with intermediate-stage HCC following the BCLC staging system, who are usually ineligible for curative resection and ablation treatments or liver transplantation; the therapies that are available for this patient subgroup are described.

    • Alejandro Forner
    • Marine Gilabert
    • Jean-Luc Raoul
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 11, P: 525-535

  • Cholangiocarcinoma (CCA) comprises heterogeneous biliary malignant tumours, and their incidence is increasing worldwide. This expert Consensus Statement, endorsed by the ENS-CCA, summarizes the latest advances in CCA, including classification, genetics and treatment, and provides recommendations for CCA management and priorities across basic, translational and clinical research.

    • Jesus M. Banales
    • Jose J. G. Marin
    • Gregory J. Gores
    ReviewsOpen Access
    Nature Reviews Gastroenterology & Hepatology
    Volume: 17, P: 557-588

  • Developments in the treatment of advanced-stage hepatocellular carcinoma include novel locoregional interventions aiming to induce tumour necrosis and systemic treatments targeting the biological mechanisms of tumour progression, thus aiming to delay progression. These approaches fiercely battle to provide the best survival, but their lack of success to date suggests that they might be better tested as a complementary approach.

    • Marco Sanduzzi-Zamparelli
    • Jordi Bruix
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 15, P: 537-538

  • Liver transplantation is the best option for patients with early-stage hepatocellular carcinoma. Here, the authors summarize the outcomes of liver transplantation, novel surgical techniques to increase the pool of donor livers for transplantation and the limitations of current priority policies.

    • Gonzalo Sapisochin
    • Jordi Bruix
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 14, P: 203-217

  • The design of clinical trials for hepatocellular carcinoma is complicated by a number of obstacles. In this Review, the authors discuss the advances in systemic therapy for hepatocellular carcinoma and critically discuss trial designs in the context of past successes and failures.

    • Jordi Bruix
    • Leonardo G. da Fonseca
    • María Reig
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 16, P: 617-630